Dexamethazone implant in the treatment of diabetic macular edema in patients with proliferative diabetic retinopathy after vitrectomy
Year: 2021, volume 17 Issue: №3 Pages: 620-624
Heading: Тhematic supplement Article type: Original article
Authors: Andreichenko О.А., Radchenko E.Yu., Melnikova Yu.A.
Organization: Saratov State Medical University, University Clinical Hospital №2 (Clinic of Eye Diseases)
Heading: Тhematic supplement Article type: Original article
Authors: Andreichenko О.А., Radchenko E.Yu., Melnikova Yu.A.
Organization: Saratov State Medical University, University Clinical Hospital №2 (Clinic of Eye Diseases)
Summary:
Purpose: to analyze the results of treatment of diabetic macular edema (DME) using intravitreal administration of anti-VEGF drugs and dexamethazone implant after vitrectomy. Material and Methods. The study involved 64 patients (64 eyes) with proliferative dibetic retinopathy and type 2 diabetes mellitus. Group 1 included 34 patients (34 eyes) with chronic DMO after vitrectomy. All patients received loading doses of an anti-VEGF drug (5 aflibercept injections) 1 month after vitrectomy (VE), followed by the introduction of a dexamethasone implant into the vitreous cavity. Patients of group 2 (16 patients (16 eyes)) received a dexamethasone implant immediately 1 month after surgery (VE). Results. The maximally corrected visual acuity (MCVA) in the 1st group increased from 0.07±0.03 to 0.36±0.12 (p=0.01)6 month after administration, the retinal thickness decreased from 487±45 to 276±29 mkm (p=0.01). In the 2nd group the visual acuity against the background of the treatment increased from 0.09±0.04 to 0.53±0.13 mkm (p=0.01) 6 month afterthe introduction of the dexamethasone implant, the thickness of the retina in the macula decreased from 499±76 to 268±16 (p=0.01). Conclusion. The use of a dexamethasone implant and anti-VEGF drugs for the treatment of DMO after VE has a positive effect.
Bibliography:
1. Astakhov YuS, Lisochkina AB, Shadrichev FE. Modern directions of drug treatment of diabetic nonproliferative retinopathy. Clinical Ophthalmus 2003; 4 (3): 96-101.
2. Astakhov YuS, Shadrichev FE, Krasavina Ml, Grigorieva NN. Modern approaches to the treatment of diabetic macular edema. Ophthalmologicheskie Vedomosti 2009; (4): 59-690.
3. BikbovMM, KudoyarovaKI.Zainullin RM, GilmanshinTR. Comparative characteristics of the results of the use of multidirectional intravitreal pharmacotherapy in the treatment of diabetic macular edema. Ophthalmosurgery 2021; (1): 39-45.
4. Zakharov VD, Shkvorchenko DO, Kakunina SA, et al. Modern methods of surgical treatment of proliferative diabetic retinopathy complicated by traction retinal detachment. Ophthalmosurgery 2020; (2): 93-9.
5. Kamenskikh TG, Batishcheva YuS, Kolbenev IO, et al. Experience in angiogenic and corticosteroid therapy of diabetic macular edema. Saratov Journal of Medical Scientific Research 2017; 13 (2): 383-8.
6. Fayzrakhmanov RR, Shishkin MM, Shatalova EO, Sukhanova AV. Early switch from anti-VEGF therapy to dexamethasone implant in diabetic macular edema. Ophthalmosurgery 2020; (4): 86-92.
7. Shadrichev FE. Diabetic retinopathy (gaze of an ophthalmologist). Ophthalmology 2008; 3: 8-11
8. Shklyarov ЕВ, Grigorieva NN, Shadrichev FE. New technologies for visualization of diabetic retinal changes. Ophthalmology 2008; 3: 28-9.
9. Brown DM, Nguyen QD, Marcus DM, et al./RISE and RIDE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-22.
10. Gonzalez VH, Campbell J, Holekamp NM. Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol 2016; 172: 72-9. DOI: 10.1016/j. ajo. 2016.09.012.
| Attachment | Size |
|---|---|
| 2021_03-2_620-624.pdf | 521.51 KB |
Русский
English